Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On August 6, Revolution Medicines, Inc. (NASDAQ:RVMD) released its financial and business update for the fiscal second quarter of 2025. The company reported advancement in its key drug Daraxonrasib, which is currently in Phase 3 trials for patients with pancreatic ductal adenocarcinoma and non-small cell lung cancer.
Wall Street is optimistic regarding this clinical-stage company, with analysts’ average 12-month price target of $72 representing 101.23% upside from the current level.
Recently, on August 15, Wells Fargo initiated coverage of Revolution Medicines, Inc. (NASDAQ:RVMD) with a Buy rating and a $67 price target. The firm noted that the company has worked on a de-risked profile for this drug, meaning that it has a lower chance of failure. The firm expects a positive result from the Phase 3 trial, which is due in 2026.
Revolution Medicines, Inc. (NASDAQ:RVMD) develops targeted cancer therapies for RAS-addicted cancers. They create drugs called RAS(ON) inhibitors that directly target specific RAS mutations.
While we acknowledge the potential of RVMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
